Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis

Heffernan, Kiera; Nikitas, Fulya Sen; Shukla, Urmi; Camejo, H Starkie; Knott, Craig

doi:10.1016/j.ygyno.2022.06.011

Cited by 16 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 Results in the context of published literature While no real-world evidence studies are available on advanced endometrial cancer patients across the five European countries included in our study, a real-world observational study conducted in England found a median OS of 10.3 months and median time-to-nexttreatment of 7.7 months in patients diagnosed with recurrent/advanced endometrial cancer between 1 January 2013 and 31 December 2018 who were immune checkpoint inhibitor-eligible and progressed and received second-line therapy. 13 The poor survival outcomes found in this study were similar to those found in our study and highlight the challenges in achieving desirable survival outcomes for this patient population in real-world clinical settings in Europe. In a retrospective study conducted in the USA in non-MSI-H/pMMR recurrent/advanced endometrial cancer patients who progressed following prior systemic therapy, median OS was 10 months and rwPFS was 5 months.…”

Section: Clinical Outcomes In Recurrent/advanced Endometrial Cancer P...supporting

confidence: 84%

Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe

Zhang,

Kelkar,

Prabhu

et al. 2024

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo evaluate real-world treatment patterns and clinical outcomes in recurrent/advanced endometrial cancer patients who progressed following prior systemic therapy in clinical practice in Europe.DesignEndometrial Cancer Health Outcomes-Europe (ECHO-EU) is a retrospective patient chart review study.SettingECHO-EU is a multicentre study conducted in the UK, Germany, Italy, France and Spain.ParticipantsPatients with recurrent/advanced endometrial cancer who progressed between 1 July 2016 and 30 June 2019 following prior first-line systemic therapy were eligible and data were collected until last available follow-up through November 2021.Primary and secondary outcome measuresData collected included patient demographics, clinical and treatment characteristics, and clinical outcomes. Kaplan-Meier analyses were performed since initiation of second-line therapy to estimate time to treatment discontinuation, real-world progression-free survival (rwPFS) and overall survival (OS).ResultsA total of 475 patients were included from EU5 countries. Median age was 69 years at advanced endometrial cancer diagnosis, 78.7% had stage IIIB–IV disease, 45.9% had Eastern Cooperative Oncology Group status ≥2 at second-line therapy initiation. In second line, a majority of patients initiated either non-platinum-based chemotherapy (55.6%) or endocrine therapy (16.2%). Physician-reported real-world overall response rate (classified as complete or partial response) to second-line therapy was 34.5%, median rwPFS was 7.4 months (95% CI 6.2 to 8.0) and median OS was 11.0 months (95% CI 9.9 to 12.3).ConclusionsPatients had poor clinical outcomes with a median OS of <1 year and rwPFS of approximately 7 months, highlighting the significant unmet medical need in pretreated recurrent/advanced endometrial cancer patients. Novel therapies with potential to improve PFS and OS over conventional therapies could provide significant clinical benefit.

show abstract

Section: Clinical Outcomes In Recurrent/advanced Endometrial Cancer P...supporting

confidence: 84%

Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe

Zhang,

Kelkar,

Prabhu

et al. 2024

BMJ Open

View full text Add to dashboard Cite

show abstract

“… 5 , 6 Chemotherapies including carboplatin, paclitaxel, cisplatin, and doxorubicin (including liposomal doxorubicin) have been among the agents commonly used. 7 , 8 However, response rates with chemotherapy in these patients are low (10%-15%) and prognosis is poor. 1 , 9 , 10 Additionally, commonly used chemotherapies can be associated with significant toxicity.…”

Section: Introductionmentioning

confidence: 99%

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

et al. 2022

View full text Add to dashboard Cite

Background There is no clear standard of care for advanced/recurrent endometrial cancer (EC) following platinum-based therapy. Dostarlimab is approved for patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced/recurrent EC. This indirect treatment comparison (ITC) assessed dostarlimab efficacy and safety from the single-arm GARNET (NCT02715284) trial compared with doxorubicin from ZoptEC (NCT01767155). Patients and Methods Patient-level data and study variables from GARNET Cohort A1 (dMMR/MSI-H EC) and the ZoptEC doxorubicin control arm were merged. Patients were matched based on eligibility criteria (main analysis population). Safety population included all patients who received treatment. The primary efficacy comparison outcome, overall survival (OS), was calculated using a Cox proportional hazards model, with adjusted stabilized inverse probability of treatment weighting. Modified assessment-scheduled matching Kaplan--Meier analysis was used for progression-free survival (PFS) and time to deterioration (TTD) in quality of life (QoL). Results In the main analysis population, median (95% CI) OS was not reached (NR; 18.0 months--NR) for dostarlimab (n = 92) and was 11.2 (10.0-13.1) months for doxorubicin (n = 233; HR: 0.41 [95% CI: 0.28-0.61]); median PFS was 12.2 (3.3-NR) and 4.9 (4.1-6.6) months, respectively. Median TTD in QoL was NR (2.5-NR; n = 61) and 4.5 (4.1-5.4; n = 188) months, respectively. Similar rates of adverse events (AEs, 11.6% vs 15.3%) and serious AEs (34.1% vs 30.1%) were observed with dostarlimab (n = 129) and doxorubicin (n = 249). Grade ≥3 AEs occurred in 48.1% vs 78.3%, respectively. Conclusion This ITC suggests a favorable benefit:risk profile for dostarlimab in patients with dMMR/MSI-H advanced/recurrent EC.

show abstract

“…Tác giả Heffernan Kvà CS tiến hành nghiên cứu hồi cứu tại Anh, kết quả nghiên cứu chỉ ra tỉ lệ ung thư biểu mô dạng nội mạc tử cung chiếm đa số (42%), kế đến là ung thư biểu mô thanh dịch (40%), ung thư biểu mô không xếp loại (7%), ung thư biểu mô tế bào sáng (5%) và ung thư biểu mô hỗn hợp (3%) [4].…”

Section: đặC đIểm Về Lâm Sàng Khi Tái Phátunclassified

Kết Quả Điều Trị Ung Thư Nội Mạc Tử Cung Tái Phát, Di Căn Bằng Liposomal Doxorubicin Tại Bệnh Viện K

Đặng,

Phùng,

Hoàng

2023

VMJ

View full text Add to dashboard Cite

Mục tiêu: Đánh giá đáp ứng điều trị và thời gian sống thêm không tiến triển trong điều trị ung thư nội mạc tử cung tái phát, di căn bằng phác đồ liposomal doxorubicin. Đối tượng và phương pháp: Nghiên cứu hồi cứu kết hợp tiến cứu trên BN ung thư nội mạc tử cung tái phát, di căn điều trị bước 2 với liposomal doxorubicin tại bệnh viện K từ tháng 6/2017 đến tháng 6/2023. Nghiên cứu ghi nhận đặc điểm lâm sàng, cận lâm sàng tại thời điểm chẩn đoán ban đầu, tại thời điểm chẩn đoán tái phát, di căn, số chu kỳ điều trị liposomal doxorubicin, đáp ứng điều trị và thời gian sống thêm không tiến triển của các bệnh nhân. Kết quả: Tổng số 56 BN ung thư nội mạc tử cung tái phát hoặc di căn được ghi nhận vào nghiên cứu. Tỉ lệ đáp ứng toàn bộ 19,7%, trong đó đáp ứng hoàn toàn 5,4% và đáp ứng một phần 14,3%. Bệnh giữ nguyên 51,8%; 28,5% BN bệnh tiến triển. Thời gian sống thêm không tiến triển là 18,3 tuần. Kết luận: Phác đồ đơn trị liệu liposomal loxorubicin có hiệu quả trên bệnh nhân ung thư nội mạc tử cung tái phát, di căn.

show abstract

Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis

Cited by 16 publications

References 31 publications

Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe

Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

Kết Quả Điều Trị Ung Thư Nội Mạc Tử Cung Tái Phát, Di Căn Bằng Liposomal Doxorubicin Tại Bệnh Viện K

Contact Info

Product

Resources

About